nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—AVPR2—urine—urinary bladder cancer	0.144	0.683	CbGeAlD
Conivaptan—AVPR2—renal system—urinary bladder cancer	0.0353	0.167	CbGeAlD
Conivaptan—Atorvastatin—UGT2B7—urinary bladder cancer	0.0257	1	CrCbGaD
Conivaptan—CYP3A4—urine—urinary bladder cancer	0.0219	0.104	CbGeAlD
Conivaptan—CYP3A4—renal system—urinary bladder cancer	0.00537	0.0254	CbGeAlD
Conivaptan—CYP3A4—female reproductive system—urinary bladder cancer	0.0043	0.0204	CbGeAlD
Conivaptan—Infestation—Thiotepa—urinary bladder cancer	0.00393	0.00515	CcSEcCtD
Conivaptan—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.00391	0.00512	CcSEcCtD
Conivaptan—Cardiac failure—Etoposide—urinary bladder cancer	0.00376	0.00492	CcSEcCtD
Conivaptan—Haematuria—Thiotepa—urinary bladder cancer	0.00375	0.00492	CcSEcCtD
Conivaptan—Dehydration—Cisplatin—urinary bladder cancer	0.00372	0.00488	CcSEcCtD
Conivaptan—Orthostatic hypotension—Cisplatin—urinary bladder cancer	0.00366	0.00479	CcSEcCtD
Conivaptan—Hypokalaemia—Cisplatin—urinary bladder cancer	0.00364	0.00477	CcSEcCtD
Conivaptan—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.00349	0.00457	CcSEcCtD
Conivaptan—Urethral disorder—Thiotepa—urinary bladder cancer	0.00346	0.00454	CcSEcCtD
Conivaptan—Diarrhoea—Mitomycin—urinary bladder cancer	0.00341	0.00447	CcSEcCtD
Conivaptan—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.00335	0.00439	CcSEcCtD
Conivaptan—Pneumonia—Gemcitabine—urinary bladder cancer	0.00333	0.00436	CcSEcCtD
Conivaptan—Cardiac disorder—Thiotepa—urinary bladder cancer	0.00328	0.00429	CcSEcCtD
Conivaptan—Pneumonia—Fluorouracil—urinary bladder cancer	0.00327	0.00429	CcSEcCtD
Conivaptan—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00325	0.00426	CcSEcCtD
Conivaptan—Infestation—Fluorouracil—urinary bladder cancer	0.00325	0.00426	CcSEcCtD
Conivaptan—Angiopathy—Thiotepa—urinary bladder cancer	0.0032	0.0042	CcSEcCtD
Conivaptan—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00318	0.00417	CcSEcCtD
Conivaptan—Vomiting—Mitomycin—urinary bladder cancer	0.00317	0.00416	CcSEcCtD
Conivaptan—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00316	0.00414	CcSEcCtD
Conivaptan—Haematuria—Gemcitabine—urinary bladder cancer	0.00316	0.00413	CcSEcCtD
Conivaptan—Headache—Mitomycin—urinary bladder cancer	0.00313	0.0041	CcSEcCtD
Conivaptan—Mental disorder—Thiotepa—urinary bladder cancer	0.00309	0.00405	CcSEcCtD
Conivaptan—Malnutrition—Thiotepa—urinary bladder cancer	0.00308	0.00403	CcSEcCtD
Conivaptan—Erythema—Thiotepa—urinary bladder cancer	0.00308	0.00403	CcSEcCtD
Conivaptan—Nausea—Mitomycin—urinary bladder cancer	0.00296	0.00388	CcSEcCtD
Conivaptan—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.00293	0.00384	CcSEcCtD
Conivaptan—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.00293	0.00383	CcSEcCtD
Conivaptan—Urethral disorder—Gemcitabine—urinary bladder cancer	0.00291	0.00382	CcSEcCtD
Conivaptan—Pneumonia—Etoposide—urinary bladder cancer	0.00284	0.00372	CcSEcCtD
Conivaptan—Anaemia—Thiotepa—urinary bladder cancer	0.00284	0.00372	CcSEcCtD
Conivaptan—Infestation NOS—Etoposide—urinary bladder cancer	0.00283	0.0037	CcSEcCtD
Conivaptan—Infestation—Etoposide—urinary bladder cancer	0.00283	0.0037	CcSEcCtD
Conivaptan—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00276	0.00361	CcSEcCtD
Conivaptan—Urine output increased—Methotrexate—urinary bladder cancer	0.00274	0.00358	CcSEcCtD
Conivaptan—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.00274	0.00358	CcSEcCtD
Conivaptan—Urethral disorder—Cisplatin—urinary bladder cancer	0.00272	0.00356	CcSEcCtD
Conivaptan—Candida infection—Epirubicin—urinary bladder cancer	0.0027	0.00354	CcSEcCtD
Conivaptan—Angiopathy—Gemcitabine—urinary bladder cancer	0.0027	0.00353	CcSEcCtD
Conivaptan—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00268	0.00351	CcSEcCtD
Conivaptan—Hypertension—Thiotepa—urinary bladder cancer	0.00265	0.00348	CcSEcCtD
Conivaptan—Sepsis—Methotrexate—urinary bladder cancer	0.00263	0.00344	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.0026	0.00341	CcSEcCtD
Conivaptan—Erythema—Gemcitabine—urinary bladder cancer	0.00259	0.00339	CcSEcCtD
Conivaptan—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00257	0.00337	CcSEcCtD
Conivaptan—Erythema—Fluorouracil—urinary bladder cancer	0.00254	0.00333	CcSEcCtD
Conivaptan—Confusional state—Thiotepa—urinary bladder cancer	0.00253	0.00332	CcSEcCtD
Conivaptan—Urinary tract disorder—Etoposide—urinary bladder cancer	0.00251	0.00328	CcSEcCtD
Conivaptan—Polyuria—Methotrexate—urinary bladder cancer	0.0025	0.00328	CcSEcCtD
Conivaptan—Candida infection—Doxorubicin—urinary bladder cancer	0.0025	0.00328	CcSEcCtD
Conivaptan—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.0025	0.00327	CcSEcCtD
Conivaptan—Infection—Thiotepa—urinary bladder cancer	0.00249	0.00327	CcSEcCtD
Conivaptan—Urethral disorder—Etoposide—urinary bladder cancer	0.00249	0.00326	CcSEcCtD
Conivaptan—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00246	0.00322	CcSEcCtD
Conivaptan—Sepsis—Epirubicin—urinary bladder cancer	0.00246	0.00322	CcSEcCtD
Conivaptan—Skin disorder—Thiotepa—urinary bladder cancer	0.00244	0.00319	CcSEcCtD
Conivaptan—Malnutrition—Cisplatin—urinary bladder cancer	0.00241	0.00316	CcSEcCtD
Conivaptan—Erythema—Cisplatin—urinary bladder cancer	0.00241	0.00316	CcSEcCtD
Conivaptan—Anaemia—Gemcitabine—urinary bladder cancer	0.00239	0.00313	CcSEcCtD
Conivaptan—Phlebitis—Epirubicin—urinary bladder cancer	0.00239	0.00313	CcSEcCtD
Conivaptan—Cardiac disorder—Etoposide—urinary bladder cancer	0.00235	0.00309	CcSEcCtD
Conivaptan—Anaemia—Fluorouracil—urinary bladder cancer	0.00235	0.00308	CcSEcCtD
Conivaptan—Angiopathy—Etoposide—urinary bladder cancer	0.0023	0.00302	CcSEcCtD
Conivaptan—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00229	0.003	CcSEcCtD
Conivaptan—Sepsis—Doxorubicin—urinary bladder cancer	0.00227	0.00298	CcSEcCtD
Conivaptan—Hypertension—Gemcitabine—urinary bladder cancer	0.00223	0.00293	CcSEcCtD
Conivaptan—Anaemia—Cisplatin—urinary bladder cancer	0.00223	0.00292	CcSEcCtD
Conivaptan—Phlebitis—Doxorubicin—urinary bladder cancer	0.00221	0.00289	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00219	0.00287	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00217	0.00284	CcSEcCtD
Conivaptan—Pain—Thiotepa—urinary bladder cancer	0.00215	0.00281	CcSEcCtD
Conivaptan—Constipation—Thiotepa—urinary bladder cancer	0.00215	0.00281	CcSEcCtD
Conivaptan—Cardiac failure—Epirubicin—urinary bladder cancer	0.00211	0.00276	CcSEcCtD
Conivaptan—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.00211	0.00276	CcSEcCtD
Conivaptan—Infection—Gemcitabine—urinary bladder cancer	0.0021	0.00275	CcSEcCtD
Conivaptan—Confusional state—Fluorouracil—urinary bladder cancer	0.00209	0.00274	CcSEcCtD
Conivaptan—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00207	0.00271	CcSEcCtD
Conivaptan—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00207	0.00271	CcSEcCtD
Conivaptan—Hyponatraemia—Epirubicin—urinary bladder cancer	0.00206	0.0027	CcSEcCtD
Conivaptan—Infection—Fluorouracil—urinary bladder cancer	0.00206	0.0027	CcSEcCtD
Conivaptan—Skin disorder—Gemcitabine—urinary bladder cancer	0.00205	0.00269	CcSEcCtD
Conivaptan—Anaemia—Etoposide—urinary bladder cancer	0.00204	0.00267	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00204	0.00267	CcSEcCtD
Conivaptan—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00204	0.00267	CcSEcCtD
Conivaptan—Body temperature increased—Thiotepa—urinary bladder cancer	0.00198	0.0026	CcSEcCtD
Conivaptan—Hypotension—Gemcitabine—urinary bladder cancer	0.00197	0.00258	CcSEcCtD
Conivaptan—Infection—Cisplatin—urinary bladder cancer	0.00195	0.00256	CcSEcCtD
Conivaptan—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.00195	0.00255	CcSEcCtD
Conivaptan—Cardiac failure—Doxorubicin—urinary bladder cancer	0.00195	0.00255	CcSEcCtD
Conivaptan—Hypotension—Fluorouracil—urinary bladder cancer	0.00194	0.00254	CcSEcCtD
Conivaptan—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00193	0.00253	CcSEcCtD
Conivaptan—Dehydration—Epirubicin—urinary bladder cancer	0.00191	0.0025	CcSEcCtD
Conivaptan—Skin disorder—Cisplatin—urinary bladder cancer	0.00191	0.0025	CcSEcCtD
Conivaptan—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.00191	0.0025	CcSEcCtD
Conivaptan—Insomnia—Gemcitabine—urinary bladder cancer	0.00191	0.0025	CcSEcCtD
Conivaptan—Hypertension—Etoposide—urinary bladder cancer	0.00191	0.0025	CcSEcCtD
Conivaptan—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00188	0.00246	CcSEcCtD
Conivaptan—Insomnia—Fluorouracil—urinary bladder cancer	0.00188	0.00246	CcSEcCtD
Conivaptan—Hypokalaemia—Epirubicin—urinary bladder cancer	0.00187	0.00245	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00187	0.00245	CcSEcCtD
Conivaptan—Hypotension—Cisplatin—urinary bladder cancer	0.00184	0.00241	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00182	0.00239	CcSEcCtD
Conivaptan—Confusional state—Etoposide—urinary bladder cancer	0.00182	0.00238	CcSEcCtD
Conivaptan—Pain—Gemcitabine—urinary bladder cancer	0.00181	0.00237	CcSEcCtD
Conivaptan—Constipation—Gemcitabine—urinary bladder cancer	0.00181	0.00237	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00179	0.00235	CcSEcCtD
Conivaptan—Infection—Etoposide—urinary bladder cancer	0.00179	0.00235	CcSEcCtD
Conivaptan—Pruritus—Thiotepa—urinary bladder cancer	0.00178	0.00233	CcSEcCtD
Conivaptan—Pain—Fluorouracil—urinary bladder cancer	0.00178	0.00233	CcSEcCtD
Conivaptan—Dehydration—Doxorubicin—urinary bladder cancer	0.00177	0.00232	CcSEcCtD
Conivaptan—Skin disorder—Etoposide—urinary bladder cancer	0.00175	0.00229	CcSEcCtD
Conivaptan—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00174	0.00228	CcSEcCtD
Conivaptan—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00174	0.00228	CcSEcCtD
Conivaptan—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.00173	0.00227	CcSEcCtD
Conivaptan—Diarrhoea—Thiotepa—urinary bladder cancer	0.00172	0.00225	CcSEcCtD
Conivaptan—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00171	0.00224	CcSEcCtD
Conivaptan—Pneumonia—Methotrexate—urinary bladder cancer	0.0017	0.00223	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.0017	0.00223	CcSEcCtD
Conivaptan—Infestation—Methotrexate—urinary bladder cancer	0.00169	0.00222	CcSEcCtD
Conivaptan—Infestation NOS—Methotrexate—urinary bladder cancer	0.00169	0.00222	CcSEcCtD
Conivaptan—Hypotension—Etoposide—urinary bladder cancer	0.00168	0.00221	CcSEcCtD
Conivaptan—Pain—Cisplatin—urinary bladder cancer	0.00168	0.0022	CcSEcCtD
Conivaptan—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00167	0.00219	CcSEcCtD
Conivaptan—Pollakiuria—Epirubicin—urinary bladder cancer	0.00164	0.00215	CcSEcCtD
Conivaptan—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00164	0.00215	CcSEcCtD
Conivaptan—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00162	0.00212	CcSEcCtD
Conivaptan—Haematuria—Methotrexate—urinary bladder cancer	0.00161	0.00211	CcSEcCtD
Conivaptan—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.0016	0.0021	CcSEcCtD
Conivaptan—Vomiting—Thiotepa—urinary bladder cancer	0.0016	0.00209	CcSEcCtD
Conivaptan—Pneumonia—Epirubicin—urinary bladder cancer	0.00159	0.00209	CcSEcCtD
Conivaptan—Infestation NOS—Epirubicin—urinary bladder cancer	0.00158	0.00208	CcSEcCtD
Conivaptan—Infestation—Epirubicin—urinary bladder cancer	0.00158	0.00208	CcSEcCtD
Conivaptan—Headache—Thiotepa—urinary bladder cancer	0.00157	0.00206	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00156	0.00204	CcSEcCtD
Conivaptan—Body temperature increased—Cisplatin—urinary bladder cancer	0.00156	0.00204	CcSEcCtD
Conivaptan—Pain—Etoposide—urinary bladder cancer	0.00154	0.00202	CcSEcCtD
Conivaptan—Constipation—Etoposide—urinary bladder cancer	0.00154	0.00202	CcSEcCtD
Conivaptan—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00154	0.00202	CcSEcCtD
Conivaptan—Pollakiuria—Doxorubicin—urinary bladder cancer	0.00152	0.00199	CcSEcCtD
Conivaptan—Haematuria—Epirubicin—urinary bladder cancer	0.00151	0.00198	CcSEcCtD
Conivaptan—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.0015	0.00197	CcSEcCtD
Conivaptan—Pruritus—Gemcitabine—urinary bladder cancer	0.00149	0.00196	CcSEcCtD
Conivaptan—Nausea—Thiotepa—urinary bladder cancer	0.00149	0.00195	CcSEcCtD
Conivaptan—Urethral disorder—Methotrexate—urinary bladder cancer	0.00149	0.00195	CcSEcCtD
Conivaptan—Feeling abnormal—Etoposide—urinary bladder cancer	0.00149	0.00195	CcSEcCtD
Conivaptan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00148	0.00194	CcSEcCtD
Conivaptan—Pneumonia—Doxorubicin—urinary bladder cancer	0.00147	0.00193	CcSEcCtD
Conivaptan—Pruritus—Fluorouracil—urinary bladder cancer	0.00147	0.00192	CcSEcCtD
Conivaptan—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00147	0.00192	CcSEcCtD
Conivaptan—Infestation—Doxorubicin—urinary bladder cancer	0.00147	0.00192	CcSEcCtD
Conivaptan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00144	0.00189	CcSEcCtD
Conivaptan—Body temperature increased—Etoposide—urinary bladder cancer	0.00143	0.00187	CcSEcCtD
Conivaptan—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00143	0.00187	CcSEcCtD
Conivaptan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00142	0.00186	CcSEcCtD
Conivaptan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00141	0.00185	CcSEcCtD
Conivaptan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.0014	0.00184	CcSEcCtD
Conivaptan—Oedema peripheral—Epirubicin—urinary bladder cancer	0.0014	0.00184	CcSEcCtD
Conivaptan—Haematuria—Doxorubicin—urinary bladder cancer	0.0014	0.00183	CcSEcCtD
Conivaptan—Urethral disorder—Epirubicin—urinary bladder cancer	0.00139	0.00183	CcSEcCtD
Conivaptan—Angiopathy—Methotrexate—urinary bladder cancer	0.00138	0.00181	CcSEcCtD
Conivaptan—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00137	0.00179	CcSEcCtD
Conivaptan—Diarrhoea—Cisplatin—urinary bladder cancer	0.00135	0.00176	CcSEcCtD
Conivaptan—Vomiting—Gemcitabine—urinary bladder cancer	0.00134	0.00176	CcSEcCtD
Conivaptan—Mental disorder—Methotrexate—urinary bladder cancer	0.00133	0.00174	CcSEcCtD
Conivaptan—Erythema—Methotrexate—urinary bladder cancer	0.00132	0.00173	CcSEcCtD
Conivaptan—Malnutrition—Methotrexate—urinary bladder cancer	0.00132	0.00173	CcSEcCtD
Conivaptan—Headache—Gemcitabine—urinary bladder cancer	0.00132	0.00173	CcSEcCtD
Conivaptan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00132	0.00173	CcSEcCtD
Conivaptan—Vomiting—Fluorouracil—urinary bladder cancer	0.00132	0.00173	CcSEcCtD
Conivaptan—Headache—Fluorouracil—urinary bladder cancer	0.0013	0.0017	CcSEcCtD
Conivaptan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.0013	0.0017	CcSEcCtD
Conivaptan—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.0013	0.0017	CcSEcCtD
Conivaptan—Angiopathy—Epirubicin—urinary bladder cancer	0.00129	0.00169	CcSEcCtD
Conivaptan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00129	0.00169	CcSEcCtD
Conivaptan—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00128	0.00168	CcSEcCtD
Conivaptan—Pruritus—Etoposide—urinary bladder cancer	0.00128	0.00167	CcSEcCtD
Conivaptan—Nausea—Gemcitabine—urinary bladder cancer	0.00125	0.00164	CcSEcCtD
Conivaptan—Vomiting—Cisplatin—urinary bladder cancer	0.00125	0.00164	CcSEcCtD
Conivaptan—Mental disorder—Epirubicin—urinary bladder cancer	0.00125	0.00163	CcSEcCtD
Conivaptan—Erythema—Epirubicin—urinary bladder cancer	0.00124	0.00162	CcSEcCtD
Conivaptan—Malnutrition—Epirubicin—urinary bladder cancer	0.00124	0.00162	CcSEcCtD
Conivaptan—Diarrhoea—Etoposide—urinary bladder cancer	0.00123	0.00162	CcSEcCtD
Conivaptan—Nausea—Fluorouracil—urinary bladder cancer	0.00123	0.00162	CcSEcCtD
Conivaptan—Anaemia—Methotrexate—urinary bladder cancer	0.00122	0.0016	CcSEcCtD
Conivaptan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00122	0.0016	CcSEcCtD
Conivaptan—Angiopathy—Doxorubicin—urinary bladder cancer	0.00119	0.00156	CcSEcCtD
Conivaptan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00119	0.00155	CcSEcCtD
Conivaptan—Nausea—Cisplatin—urinary bladder cancer	0.00117	0.00153	CcSEcCtD
Conivaptan—Mental disorder—Doxorubicin—urinary bladder cancer	0.00115	0.00151	CcSEcCtD
Conivaptan—Vomiting—Etoposide—urinary bladder cancer	0.00115	0.0015	CcSEcCtD
Conivaptan—Erythema—Doxorubicin—urinary bladder cancer	0.00115	0.0015	CcSEcCtD
Conivaptan—Malnutrition—Doxorubicin—urinary bladder cancer	0.00115	0.0015	CcSEcCtD
Conivaptan—Anaemia—Epirubicin—urinary bladder cancer	0.00114	0.0015	CcSEcCtD
Conivaptan—Headache—Etoposide—urinary bladder cancer	0.00113	0.00148	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00112	0.00147	CcSEcCtD
Conivaptan—Confusional state—Methotrexate—urinary bladder cancer	0.00109	0.00143	CcSEcCtD
Conivaptan—Infection—Methotrexate—urinary bladder cancer	0.00107	0.00141	CcSEcCtD
Conivaptan—Nausea—Etoposide—urinary bladder cancer	0.00107	0.0014	CcSEcCtD
Conivaptan—Hypertension—Epirubicin—urinary bladder cancer	0.00107	0.0014	CcSEcCtD
Conivaptan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00106	0.00139	CcSEcCtD
Conivaptan—Anaemia—Doxorubicin—urinary bladder cancer	0.00106	0.00139	CcSEcCtD
Conivaptan—Skin disorder—Methotrexate—urinary bladder cancer	0.00105	0.00137	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00105	0.00137	CcSEcCtD
Conivaptan—Dry mouth—Epirubicin—urinary bladder cancer	0.00103	0.00135	CcSEcCtD
Conivaptan—Confusional state—Epirubicin—urinary bladder cancer	0.00102	0.00133	CcSEcCtD
Conivaptan—Hypotension—Methotrexate—urinary bladder cancer	0.00101	0.00132	CcSEcCtD
Conivaptan—Infection—Epirubicin—urinary bladder cancer	0.001	0.00132	CcSEcCtD
Conivaptan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000991	0.0013	CcSEcCtD
Conivaptan—Hypertension—Doxorubicin—urinary bladder cancer	0.000989	0.0013	CcSEcCtD
Conivaptan—Skin disorder—Epirubicin—urinary bladder cancer	0.000982	0.00129	CcSEcCtD
Conivaptan—Insomnia—Methotrexate—urinary bladder cancer	0.000977	0.00128	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000969	0.00127	CcSEcCtD
Conivaptan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000954	0.00125	CcSEcCtD
Conivaptan—Hypotension—Epirubicin—urinary bladder cancer	0.000944	0.00124	CcSEcCtD
Conivaptan—Confusional state—Doxorubicin—urinary bladder cancer	0.000943	0.00124	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000932	0.00122	CcSEcCtD
Conivaptan—Infection—Doxorubicin—urinary bladder cancer	0.000929	0.00122	CcSEcCtD
Conivaptan—Pain—Methotrexate—urinary bladder cancer	0.000923	0.00121	CcSEcCtD
Conivaptan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000917	0.0012	CcSEcCtD
Conivaptan—Insomnia—Epirubicin—urinary bladder cancer	0.000914	0.0012	CcSEcCtD
Conivaptan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000908	0.00119	CcSEcCtD
Conivaptan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00089	0.00117	CcSEcCtD
Conivaptan—Hypotension—Doxorubicin—urinary bladder cancer	0.000874	0.00114	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000872	0.00114	CcSEcCtD
Conivaptan—Pain—Epirubicin—urinary bladder cancer	0.000864	0.00113	CcSEcCtD
Conivaptan—Constipation—Epirubicin—urinary bladder cancer	0.000864	0.00113	CcSEcCtD
Conivaptan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000854	0.00112	CcSEcCtD
Conivaptan—Insomnia—Doxorubicin—urinary bladder cancer	0.000846	0.00111	CcSEcCtD
Conivaptan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000833	0.00109	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000807	0.00106	CcSEcCtD
Conivaptan—Constipation—Doxorubicin—urinary bladder cancer	0.0008	0.00105	CcSEcCtD
Conivaptan—Pain—Doxorubicin—urinary bladder cancer	0.0008	0.00105	CcSEcCtD
Conivaptan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000799	0.00105	CcSEcCtD
Conivaptan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00077	0.00101	CcSEcCtD
Conivaptan—Pruritus—Methotrexate—urinary bladder cancer	0.000764	0.001	CcSEcCtD
Conivaptan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000739	0.000968	CcSEcCtD
Conivaptan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000739	0.000968	CcSEcCtD
Conivaptan—Pruritus—Epirubicin—urinary bladder cancer	0.000715	0.000937	CcSEcCtD
Conivaptan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000691	0.000906	CcSEcCtD
Conivaptan—Vomiting—Methotrexate—urinary bladder cancer	0.000687	0.000899	CcSEcCtD
Conivaptan—Headache—Methotrexate—urinary bladder cancer	0.000676	0.000886	CcSEcCtD
Conivaptan—Pruritus—Doxorubicin—urinary bladder cancer	0.000662	0.000867	CcSEcCtD
Conivaptan—Vomiting—Epirubicin—urinary bladder cancer	0.000643	0.000842	CcSEcCtD
Conivaptan—Nausea—Methotrexate—urinary bladder cancer	0.000641	0.00084	CcSEcCtD
Conivaptan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00064	0.000838	CcSEcCtD
Conivaptan—Headache—Epirubicin—urinary bladder cancer	0.000633	0.000829	CcSEcCtD
Conivaptan—Nausea—Epirubicin—urinary bladder cancer	0.0006	0.000786	CcSEcCtD
Conivaptan—Vomiting—Doxorubicin—urinary bladder cancer	0.000594	0.000779	CcSEcCtD
Conivaptan—Headache—Doxorubicin—urinary bladder cancer	0.000586	0.000767	CcSEcCtD
Conivaptan—Nausea—Doxorubicin—urinary bladder cancer	0.000555	0.000728	CcSEcCtD
